How does StarDrop compare to Semeta?
What are StarDrop and Semeta? Semeta is a tailored platform for DMPK scientists. It enables users to address key challenges…
What are StarDrop and Semeta? Semeta is a tailored platform for DMPK scientists. It enables users to address key challenges…
What comprises large molecules? When we talk about “large molecules,” we often think of biologics like monoclonal antibodies, proteins, and…
StarDrop — A Swiss Army knife for drug discovery It’s designed to fit right in with the other tools you…
At a very basic level, this means that StarDrop supports loading data from many different standard file formats (SDF, MOL2,…
Finding the right fit There’s no one-size-fits-all solution when it comes to data visualisation and analysis tools for drug development…
Develop advanced MPO strategies and target the right compounds, faster.
We’re diving back into our favourite subject: multi-parameter optimisation.
Is AI-guided drug discovery faster and cheaper? The evidence for this is, by definition, anecdotal. No one runs the same…
What’s the purpose of a predictive model? What’s the value of predictive models for drug discovery? Most of the undergraduate…
The role of generative chemistry in drug discovery A key difficulty in finding new drugs is the sheer size of…
In this paper, we describe an extended benchmark for non-cognate docking of macrocyclic ligands, and the superior performance of Surflex-Dock…
Discover which metabolite prediction software is best for your needs in this comprehensive guide from Optibrium. Compare top tools like Meteor Nexus, MetaSite, and StarDrop to make informed decisions for drug metabolism prediction
How number of users affect drug discovery software costs The number of people who need access to the platform is…
In this ebook, you’ll discover the key considerations which every leader needs to take in order to successfully implement AI in their drug discovery pipelines.
Successful drugs require a delicate balance of many properties, such as potency, ADME and toxicity, to meet a project’s therapeutic objective. To make decisions about compound progression and assay selection, the available data must be assessed against project-specific criteria. However, the data on which we base our decisions often come from different sources and can vary in quality, so how can we use this information to make confident decisions? In addition, how can we be sure that the criteria we’re using are the most appropriate?
In this ebook we demonstrate our deployable AI discovery platform, Cerella™. Browse real-world stories of success from our collaborations with AstraZeneca, Genetech, Takeda Pharmaceuticals, Constellation Pharmaceuticals and many more.
Generative molecular design provides new exciting avenues of chemical space exploration. But how can we use these methods effectively to assess many optimisation strategies and find the compounds destined for success in our projects?
Join Dr Matt Segall and Dr Michael Parker as they explore state-of-the-art generative chemistry, and discuss the importance of an augmented intelligence approach for successful discovery.
This peer-reviewed paper in Xenobiotica describes a new method to determine the most likely experimentally-observed routes of metabolism and metabolites based on our WhichP450™, regioselectivity and new WhichEnzyme™ model.